Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

The Lancet

Volumn 373, Issue 9667, 2009, Pages 929-940

  Kotseva, Kornelia ^a   Wood, David ^a   De Backer, Guy ^b   De Bacquer, Dirk ^b   Pyörälä, Kalevi ^c   Keil, Ulrich ^d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; CROSS-SECTIONAL STUDY; CZECH REPUBLIC; DIABETES MELLITUS; EUROPE; FEMALE; FINLAND; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HOSPITAL; HOSPITAL ADMISSION; HUMAN; HUNGARY; HYPERTENSION; INTERMETHOD COMPARISON; INTERVIEW; ITALY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SELF REPORT; SLOVENIA;

EID: 61849116330     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60330-5     Document Type: Article

References (38)

1. Allender S., Scharbotough P., Peto V., et al. European cardiovascular disease statistics: 2008 edition (2008), British Heart Foundation, London
2. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., and Murray C.J.L. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2006) 1747-1757
3. Leal J., Luengo-Fernández R., Gray A., Petersen S., and Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27 (2006) 1610-1619
4. Pyörälä K., De Backer G., Graham I., Poole-Wilson P.A., and Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15 (1994) 1300-1331
5. Wood D., De Backer G., Faergeman D., Graham I., Mancia G., and Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 19 (1998) 1434-1503
6. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10 suppl 1 (2003) S1-S78
7. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 suppl 2 (2007) S1-S113
8. Taylor R., Brown A., Ebrahim S., et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomised controlled trials. Am J Med 116 (2004) 682-692
9. Clark A.M., Hartling L., Vandermeer B., and McAlister F.A. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 143 (2005) 659-672
10. McAlsiter F.A., Lawson F., Teo K.K., and Armstrong P.W. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 323 (2001) 957-962
11. Kotseva K., Wood D.A., De Bacquer D., Heidrich J., and De Backer G. Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey. Eur Heart J 6 suppl J (2004) J17-J26
12. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 18 (1997) 1569-1582
13. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-572
14. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357 (2001) 995-1001
15. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyörälä K., Keil U., and for the EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty two European countries. Eur J Cardiovasc Prev Rehabil 16 (2009) 121-137
16. Middleton E.T., and Morice A.H. Breath carbon monoxide as an indication of smoking habit. Chest 117 (2000) 758-763
17. Sundvall J., Leiviskä J., Alfthan G., and Vartiainen E. Serum cholesterol during 27 years: assessment of systematic error and affecting factors and their role in interpreting population trends. Clin Chim Acta 378 (2007) 93-98
18. Lemeshow S., Hosmer D., Klar J., and Lwanga S. Adequacy of sample size in health studies (1990), John Wiley, New York
19. Brown H., and Prescott R. Applied mixed models in medicine (2006), John Wiley & Sons, New York
20. Wilson K., Gibson N., Willan A., and Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 160 (2000) 939-944
21. Silagy C., and Stead L. Physican advice for smoking cessation (Cochrane Review). The Cochrane Library 2 (2002) Oxford: Update Software
22. Raw M., McNeill A., and West R. Smoking correction: evidence based recommendations for the health care system. BMJ 318 (1999) 182-185
23. Balfour D., Benowitz N., Fagerström K., Kunze M., and Keil U. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. Eur Heart J 21 (2000) 438-445
24. Wu P., Wilson K., Dimoulas P., and Mills E.J. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 6 (2006) 300
25. Klein S., Burke L.E., Bray G.A., et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110 (2004) 2952-2967
26. Gerin W., Ogedegbe G., Schwartz J.E., et al. Assessment of the white coat effect. J Hypertens 24 (2006) 51-58
27. Freemantle N., Cleland J., Young P., Mason J., and Harrisson J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999) 1730-1807
28. Domanski M.J., Exner D.V., Borkowf C.B., Geller N.L., Rosenberg Y., and Pfeffer M.A. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 33 (1999) 598-604
29. Law M.R., Wald N.J., and Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 308 (1994) 367-372
30. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423-1429
31. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
32. Holmann R.R., Paul S.E., Bethel M.A., Matthews D.R., and Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
33. De Velasco J.A., Cosin J., Lopez-Sendon J.L., et al. Secondary prevention of myocardial infarction in Spain. The PREVESE study. Rev Esp Cardiol 50 (1997) 406-415 (in Spanish).
34. De Velasco J.A., Cosin J., Lopez-Sendon J.L., De Teresa E., De Oya M., and Sellers G. New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study. Rev Esp Cardiol 55 (2002) 801-809 (in Spanish).
35. Danchin N., Hanania G., Grenier O., et al. Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys. Ann Cardiol Angeiol 52 (2003) 1-6 (in French).
36. Reiner Z., Mihatov S., Miličić D., Bergovec M., and Planinc D. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehab 13 (2006) 646-654
37. Giannuzzi P., Saner H., Bjornstad H., et al. Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur Heart J 24 (2003) 1273-1278
38. Wood D.A., Kotseva K., Connolly S., et al. Nurse-coordinated multidisciplinary, family-based cardiovascular desease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired cluster randomised controlled trial. Lancet 371 (2008) 1999-2012